OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
OKYO Pharma's Chief Medical Officer, Flavio Mantelli, purchased 20,000 ordinary shares at $1.40 per share on NASDAQ. The company is a clinical-stage biopharmaceutical firm focused on therapies for neuropathic corneal pain and anterior segment eye diseases.
Key figures
- Purchase price
- 1.4
- Shares purchased
- 20000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.